Source link : https://www.newshealth.biz/health-news/fda-approves-vorasidenib-for-idh-mutant-gliomas/
The FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug — an IDH1 and IDH2 inhibitor — is the first systemic therapy approved for this patient population and can be administered following surgery (either biopsy, sub-total resection, or gross […]
Author : News Health
Publish date : 2024-08-06 21:44:24
Copyright for syndicated content belongs to the linked Source.
Categories